STRS Ohio’s Crinetics Pharmaceuticals CRNX Stock Holding History

STRS Ohio’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131K	Hold	3,500	–	–	﹤0.01%	1776
2026 Q1	$127K	Sell	3,500 -1,800	-34%	-$80.4K	﹤0.01%	1692
2025 Q4	$247K	Buy	5,300 +4,100	+342%	+$183K	﹤0.01%	1425
2025 Q3	$50K	Sell	1,200 -500	-29%	-$16K	﹤0.01%	2004
2025 Q2	$48.9K	Sell	1,700 -2,000	-54%	-$61.8K	﹤0.01%	2029
2025 Q1	$124K	Sell	3,700 -3,200	-46%	-$120K	﹤0.01%	1622
2024 Q4	$353K	Buy	6,900 +2,200	+47%	+$123K	﹤0.01%	1328
2024 Q3	$240K	Sell	4,700 -2,400	-34%	-$124K	﹤0.01%	1512
2024 Q2	$318K	Buy	7,100 +6,700	+1,675%	+$309K	﹤0.01%	1424
2024 Q1	$18K	Buy	+400	New	+$15.7K	﹤0.01%	1859
2019 Q1	–	Sell	-2,000	Closed	-$59K	–	2057
2018 Q4	$59K	Hold	2,000	–	–	﹤0.01%	1850
2018 Q3	$57K	Buy	+2,000	New	+$59.4K	﹤0.01%	1928

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

STRS Ohio's CRNX Position: Q2 2026 in Review

STRS Ohio held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 3,500 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1776.

STRS Ohio first reported a position in CRNX in Q3 2018 and has held it in 12 quarters since. The position peaked at $353K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

STRS Ohio held 3,500 shares of Crinetics Pharmaceuticals worth $131K as of Q2 2026.
STRS Ohio left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1776 holding.
STRS Ohio first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
STRS Ohio's Crinetics Pharmaceuticals position peaked at $353K in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.